Business Wire: Rho Selects Medidata’s Industry-Leading Decentralized Clinical Trial (DCT) Capabilities for Patient-Focused Approach to New Drug Development

November 2, 2021

Medidata, a Dassault Systèmes company, today announced that Rho, a full-service contract research organization (CRO) with a proven track record of drug development success, is using Medidata to standardize its clinical trial platform for building out its decentralized clinical trial (DCT) technology offerings. This will enable Rho to provide rapid reporting of cross-domain, cross-study data in decentralized trials, where data collection methods have become more numerous, varied, and complex.

“Forward-thinking CROs, such as Rho, are rapidly making the necessary platform and accreditation investments to enable sponsors to move into a hybrid and/or fully decentralized approach to managing clinical trials,” said Joan Shaiman, senior vice president, partners at Medidata. “Rho has been a valued partner with Medidata for over ten years and provides its clients with deep clinical trial management expertise in neurology, respiratory, rare diseases and orphan drugs.”

Read the full article here.